What is it about?
A new and efficient synthetic route for dual-Src/Abl kinase inhibitor dasatinib (Sprycel®), an anticancer drug, is described. This commercially viable process yields dasatinib monohydrate free of potential impurities with consistent yield of 68% in route A and 61% in route B with HPLC purity >99.80% over four stages.
Featured Image
Why is it important?
It is a convenient new and efficient commercial synthetic route for dasatinib (Sprycel®), an anticancer drug,
Read the Original
This page is a summary of: A convenient new and efficient commercial synthetic route for dasatinib (Sprycel®), Synthetic Communications, June 2017, Taylor & Francis,
DOI: 10.1080/00397911.2017.1337150.
You can read the full text:
Contributors
The following have contributed to this page
